Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer

Clinical Imaging

Volumn 21, Issue 5, 1997, Pages 332-336

  Inoue, Tomio ^a   Kim, E Edmund ^a   Wallace, Sidney ^a   Yang, David J ^a   Wong, Franklin C L ^a   Bassa, Pedro ^a   Buzdar, Aman U ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

18F fluorotamoxifen; Breast cancer; Cardioprotection; Heart; PET

Indexed keywords

CHOLESTEROL; FLUORINE 18; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG UPTAKE; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SYMPTOM;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; HEART; HUMANS; MIDDLE AGED; MYOCARDIUM; NEOPLASMS, HORMONE-DEPENDENT; PILOT PROJECTS; POSTMENOPAUSE; TAMOXIFEN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030664349     PISSN: 08997071     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-7071(96)00084-8     Document Type: Article

References (21)

1. Schapira DV, Kumar NB, Lyman GH. Serum cholesterol reduction with tamoxifen. Breast Cancer Res Treat 1990;17:3-7.
2. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan C, Feyzi J, DeMets DL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115;860-864.
3. McDonald CC, Stewart JH for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Brit Med J 1991;303:435-437.
4. Rutqvist LE, Mattsson A for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398-1406.
5. 18F]fluorotamoxifen for imaging breast tumors. Drug Targeting 1993;1:259-267.
6. Yang DJ, Li C, Kuang L-R, Price JE, Buzdar AU, Tansey W, Cherif A, Gretzer M, Kim EE, Wallace S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 1994;55:53-67.
7. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biotherapy & Radiopharmaceuticals 1996; 11(4):235-245.
8. Mullani NA, Gould KL, Hartz RK, Hitchens RE, Wong W-H, Bristow D, Adler S, Philippe EA, Gibbs B. Design and performance of Posicam 6.5 BGO positron camera. J Nucl Med 1990;31:610-616.
9. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxyglucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.
10. Lien EA, Solheim, E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991:51:4837-4844.
11. 18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-1531.
12. Mintun MA, Welch MJ, Siegeal BA, Mathias, CJ, Brodack JW, McGuire AH, Katzonellenbogen JA. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-48.
13. Kenady DE, Pavlik EJ, Nelson K, van Nagell JR, Gallion H, DePriesdt PD, Ryo UY, Baranczuk R. Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine I 123 at 16α. Arch Surg 1993;128:1373-1381.
14. Wiseman H, Cannon M, Arnstein HRV. Tamoxifen inhibits lipid peroxidation in cardiac microsomes: comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen. Biochem Pharmacol 1993;45:1851-1855.
15. Wiseman H, Paganga G, Rice-Evans, C, Halliwell B. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? Biochem J 1993;292:635-638.
16. Thangaraju M, Vijayalakshmi T, Sachdanandam P. Effect of tamoxifen on lipid peroxide and antioxidative system in postmenopausal women with breast cancer. Cancer 1994;74: 78-82.
17. Yagi K. Lipid; peroxides and human diseases. Chem Phys Lipids 1987;45:337-351.
18. Altmore E, Vendemiale G, Procacci V. Increased lipid peroxidation in diabetic patients. Diabetologia 1988;31:347-353.
19. O'Brian CA, Liskamp RM, Solomon DH, Weinstien JB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985;45: 2462-2465.
20. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res 1994;75: 586-590.
21. Batra S. Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes. Cancer Chemother Pharmacol 1990;26: 310-312.